Sensitization of cancer cells treated with cytotoxic drugs to fas- mediated cytotoxicity

Journal of the National Cancer Institute

Volumn 89, Issue 11, 1997, Pages 783-789

  Micheau, Olivier ^a   Solary, Eric ^a   Hammann, Arlette ^a   Martin, François ^a   Dimanche Boitrel, Marie Thérèse ^a  

^a U de Form et de Rech de Med ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; FAS ANTIGEN; FLUOROURACIL; MEMBRANE RECEPTOR; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; LEUKEMIA; NATURAL KILLER CELL;

EID: 0030966954     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.11.783     Document Type: Article

References (43)

1. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-39.
2. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci 1996;85: 824-7.
3. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990;82:749-55.
4. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
5. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-7.
7. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
8. Krammer PH, Dhein J, Walczak H. Berhmann I, Mariani S, Matiba B, et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142:175-91.
9. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994; 57:371-7.
10. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
11. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
12. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
13. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-13.
14. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-8.
15. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996;156:2693-9.
16. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994;370: 650-2.
17. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-43.
18. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
19. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
20. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270: 1189-92.
21. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
22. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implication for tumor immune escape. Science 1996;274:1363-6.
23. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-8.
24. Dimanche-Boitrel MT, Pelletier H, Genne P, Petit JM, Le Grimellec C, Canal P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 1992;50:667-82.
25. Martinez-Lorenzo MJ, Alava MA, Anel A, Pineiro A, Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 1996;89:511-7.
26. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791-8.
27. Lebel M, Bertrand R, Mes-Masson AM. Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Oncogene 1996;12:1127-35.
28. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995;11:1157-64.
29. Ni R, Tomita Y, Matsuda K, Ichihara A, Ishimura K, Ogasawara J, et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994;215:332-7.
30. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, et al. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 1995;17:51-61.
31. Matsumoto Y, Hayakawa A, Tamada Y, Mori H, Ohashi M. Upregulated expression of Fas antigen on cultured human keratinocytes with induction of apoptosis by cisplatin. Arch Dermatol Res 1996;288:267-9.
32. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996;157:2909-15.
33. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
34. Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Okkawara A. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN-γ-treated cultured keratinocytes. Arch Dermatol Res 1995;287:315-20.
35. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
36. Dubrez L, Savoy I, Hammann A, Solary E. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 1996;15:5504-12.
37. Montel AH, Bochan MR, Goebel WS, Brahmi Z. Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 1995;165:312-7.
38. Peng SL, Robert ME, Hayday AC, Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996;184:1149-54.
39. Falk MH, Trauth BC, Debatin KM, Klas C, Gregory CD, Rickinson AB, et al. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 1992;79: 3300-6.
40. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 1990;335:497-500.
41. Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci U S A 1990;87:9620-4.
42. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice [published erratum appears in Nature 1993;365:568]. Nature 1993;364:806-9.
43. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993;53:2591-6.